These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12001538)

  • 1. [Pilot study of the effectiveness of combination therapy with reduced dose alteplase and the glycoprotein IIb/IIIa antagonist tirofiban in acute myocardial infarct].
    Peters S; Trümmel M; Brattström A; Meyners W
    Z Kardiol; 2002 Mar; 91(3):233-7. PubMed ID: 12001538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction.
    Martínez-Ríos MA; Rosas M; González H; Peña-Duque MA; Martínez-Sánchez C; Gaspar J; García H; Gaxiola E; Delgado L; Carrillo J; Leyva JL; Lupi E;
    Am J Cardiol; 2004 Feb; 93(3):280-7. PubMed ID: 14759375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
    Hermanides RS; van Werkum JW; Ottervanger JP; Breet NJ; Gosselink AT; van Houwelingen KG; Dambrink JH; Hamm C; ten Berg JM; van 't Hof AW;
    Catheter Cardiovasc Interv; 2012 May; 79(6):956-64. PubMed ID: 22162050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
    Talarico GP; Brancati M; Burzotta F; Porto I; Trani C; De Vita M; Todaro D; Giammarinaro M; Leone AM; Niccoli G; Andreotti F; Mazzari MA; Schiavoni G; Crea F
    J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):245-51. PubMed ID: 19262211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tirofiban on angiographic morphologic features of high-burden thrombus formation during direct percutaneous coronary intervention and short-term outcomes.
    Yip HK; Wu CJ; Chang HW; Hsieh YK; Fang CY; Chen SM; Chen MC
    Chest; 2003 Sep; 124(3):962-8. PubMed ID: 12970024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and feasibility of a novel dosing regimen of tirofiban administered in patients with acute myocardial infarction with ST elevation before primary coronary angioplasty: a pilot study.
    Kochman W; Dobrzycki S; Nowak KS; Chlopicki S; Kralisz P; Prokopczuk P; Bachorzewska-Gajewska H; Gugala K; Niewada M; Mezynski G; Poniatowski B; Korecki J; Musial WJ
    J Thromb Thrombolysis; 2004 Apr; 17(2):127-31. PubMed ID: 15306748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.
    Sarullo FM; Pasquale PD; D'Alfonso G; Amerigo L; Cannizzaro S; Castello A
    Ital Heart J; 2001 Aug; 2(8):605-11. PubMed ID: 11577835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facilitated PCI by combination fibrinolysis or upstream tirofiban in acute ST-segment elevation myocardial infarction: results of the Alteplase and Tirofiban in Acute Myocardial Infarction (ATAMI) trial.
    Peters S; Truemmel M; Koehler B
    Int J Cardiol; 2008 Nov; 130(2):235-40. PubMed ID: 18055037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
    Zhao XQ; Théroux P; Snapinn SM; Sax FL
    Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter randomized trial of facilitated percutaneous coronary intervention with low-dose tenecteplase in patients with acute myocardial infarction: the Athens PCI trial.
    Kanakakis J; Nanas JN; Tsagalou EP; Maroulidis GD; Drakos SG; Ntalianis AS; Tzoumele P; Skoumbourdis E; Charbis P; Rokas S; Anastasiou-Nana M
    Catheter Cardiovasc Interv; 2009 Sep; 74(3):398-405. PubMed ID: 19360864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
    Gibson CM; Goel M; Cohen DJ; Piana RN; Deckelbaum LI; Harris KE; King SB
    J Am Coll Cardiol; 1998 Jul; 32(1):28-34. PubMed ID: 9669245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tirofiban therapy on ST segment resolution and clinical outcomes in patients with ST segment elevated acute myocardial infarction undergoing primary angioplasty.
    Uyarel H; Uzunlar B; Unal Dayi S; Tartan Z; Samur H; Kasikcioglu H; Akgul O; Simsek D; Erdem I; Okmen E; Cam N
    Cardiology; 2006; 105(3):168-75. PubMed ID: 16479104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
    Valgimigli M; Tebaldi M; Campo G; Gambetti S; Bristot L; Monti M; Parrinello G; Ferrari R;
    JACC Cardiovasc Interv; 2012 Mar; 5(3):268-77. PubMed ID: 22440491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
    Di Pasquale P; Sarullo FM; Cannizzaro S; Vitrano MG; Giubilato A; Scalzo S; Giambanco F; Paterna S
    Ital Heart J; 2001 Oct; 2(10):751-6. PubMed ID: 11721719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful recanalization of an occluded coronary artery by percutaneous coronary intervention, systemic administration of tirofiban, a glycoprotein IIb/IIIa inhibitor, and intracoronary thrombolysis with alteplase.
    Meyners W; Peters S; Trümmel M; Koehler B
    Z Kardiol; 2004 May; 93(5):407-12. PubMed ID: 15160277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial.
    Lee DP; Herity NA; Hiatt BL; Fearon WF; Rezaee M; Carter AJ; Huston M; Schreiber D; DiBattiste PM; Yeung AC;
    Circulation; 2003 Mar; 107(11):1497-501. PubMed ID: 12654606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous glycoprotein IIb/IIIa inhibitor (tirofiban) followed by intra-arterial urokinase and mechanical thrombolysis in stroke.
    Mangiafico S; Cellerini M; Nencini P; Gensini G; Inzitari D
    AJNR Am J Neuroradiol; 2005; 26(10):2595-601. PubMed ID: 16286408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
    Cohen M; Théroux P; Weber S; Laramée P; Huynh T; Borzak S; Diodati JG; Squire IB; Deckelbaum LI; Thornton AR; Harris KE; Sax FL; Lo MW; White HD
    Int J Cardiol; 1999 Dec; 71(3):273-81. PubMed ID: 10636535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
    Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
    Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.